In patients with nonvalvular atrial fibrillation, the average direct cost of in-hospital care for gastrointestinal hemorrhage associated with oral anticoagulants was USD 872 per patient.
Cohort (n=59)
Sí
What are the resource utilization and costs associated with in-hospital treatment of gastrointestinal hemorrhage in patients with nonvalvular atrial fibrillation treated with oral anticoagulants?
In-hospital management of gastrointestinal hemorrhage in patients with nonvalvular atrial fibrillation on oral anticoagulants generates significant healthcare costs and resource utilization.
Oral anticoagulants (OACs) used to treat nonvalvular atrial fibrillation (NVAF) are frequently associated with complications, especially gastrointestinal hemorrhage (GH). The aim was to determine the use of resources and costs in the in-hospital treatment of GH in a group of patients with NVAF from Colombia. This was a retrospective study of a cohort of patients who were diagnosed with NVAF and treated with an OAC (apixaban, rivaroxaban, dabigatran or warfarin) between 2018 and 2022 and who were hospitalized for GH. Information on diagnoses, GH location, administered medications, procedures, hospital stay, and health care costs was collected, adjusted to 2022. In total, 59 patients from nine different cities were identified, the mean age was 82.9 ± 12.6 years, and most were men (61.0%) who were admitted to nine clinics for GH. Upper GH was the most frequently identified form (78.0%). The most commonly used OACs were apixaban (44.1%), rivaroxaban (35.6%), warfarin (15.3%) and dabigatran (5.1%). The mean hospital stay was 6.4 ± 5.9 days, and 18.3% of the patients were admitted to the intensive care unit. Patients also received medications that increase the risk of bleeding, such as acetylsalicylic acid (45.8%), the antiplatelet inhibitor P2Y12 (15.3%) and systemic glucocorticoids (23.7%). The average direct cost of all hospital care was USD 872 ± 1315 per patient, which corresponds to 13% of the country’s gross domestic product per capita. GH patients with NVAF generates a significant cost for the use of resources such as medications, procedures and care that affect the country’s health system.
Machado‐Duque et al. (Sat,) conducted a cohort in Nonvalvular atrial fibrillation with gastrointestinal hemorrhage (n=59). Oral anticoagulants (apixaban, rivaroxaban, dabigatran, or warfarin) was evaluated on Average direct cost of hospital care per patient (USD). In patients with nonvalvular atrial fibrillation, the average direct cost of in-hospital care for gastrointestinal hemorrhage associated with oral anticoagulants was USD 872 per patient.